US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
US7544511B2
(en)
*
|
1996-09-25 |
2009-06-09 |
Neuralstem Biopharmaceuticals Ltd. |
Stable neural stem cell line methods
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
HUP0104708A3
(en)
*
|
1998-12-31 |
2004-05-28 |
Sod Conseils Rech Applic |
Prenyl transferase inhibitors and medicaments containing them
|
WO2003000180A2
(en)
|
2001-06-20 |
2003-01-03 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
DE60209348T2
(de)
|
2001-06-20 |
2006-10-12 |
Merck & Co., Inc. |
Dipeptidylpeptidase-hemmer zur behandlung von diabetes
|
KR20040015298A
(ko)
|
2001-06-27 |
2004-02-18 |
스미스클라인 비참 코포레이션 |
디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
EP1476178A4
(de)
*
|
2002-02-14 |
2009-08-26 |
Bayer Pharmaceuticals Corp |
Formulierungsstrategien zur stabilisierung von peptiden in organischen lösungsmitteln und in getrockneten zuständen
|
US7307164B2
(en)
|
2002-03-25 |
2007-12-11 |
Merck & Co., Inc. |
β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
ATE451369T1
(de)
*
|
2002-07-15 |
2009-12-15 |
Merck & Co Inc |
Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1554280B1
(de)
*
|
2002-10-07 |
2007-08-15 |
Merck & Co., Inc. |
Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
|
BR0315381A
(pt)
*
|
2002-10-18 |
2005-08-23 |
Merck & Co Inc |
Composto ou um sal farmaceuticamente aceitável deste, composição farmacêutica, e, métodos para inibir a atividade da enzima dipeptidil peptidase-iv em um mamìfero em necessidade disto, para tratar diabetes em um mamìfero em necessidade disto, para tratar diabete não dependente de insulina (tipo 2) em um mamìfero em necessidade disto, para tratar hiperglicemia em um mamìfero em necessidade disto, para tratar a obesidade em um mamìfero em necessidade disto, para tratar um ou mais distúrbios de lipìdios selecionados do grupo de dislipidemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, hdl baixo e ldl alto em um mamìfero em necessidade disto, e para tratar em um mamìfero em necessidade disto uma ou mais condições
|
EP1562925B1
(de)
|
2002-11-07 |
2007-01-03 |
Merck & Co., Inc. |
Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
|
CA2508487A1
(en)
*
|
2002-12-04 |
2004-06-17 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US8293488B2
(en)
|
2002-12-09 |
2012-10-23 |
Neuralstem, Inc. |
Method for screening neurogenic agents
|
AU2003293409A1
(en)
*
|
2002-12-09 |
2004-06-30 |
Karl K. Johe |
Method for discovering neurogenic agents
|
ATE404191T1
(de)
*
|
2002-12-10 |
2008-08-15 |
Novartis Pharma Ag |
Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist
|
AU2003297219A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
AU2004205642C1
(en)
|
2003-01-14 |
2012-01-12 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
AU2004206812A1
(en)
*
|
2003-01-17 |
2004-08-05 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP2006516573A
(ja)
*
|
2003-01-31 |
2006-07-06 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
|
AR043443A1
(es)
*
|
2003-03-07 |
2005-07-27 |
Merck & Co Inc |
Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
|
AR043505A1
(es)
*
|
2003-03-18 |
2005-08-03 |
Merck & Co Inc |
Preparacion de beta-cetoamidas e intermediarios de reaccion
|
AR043515A1
(es)
|
2003-03-19 |
2005-08-03 |
Merck & Co Inc |
Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
|
WO2004085661A2
(en)
*
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc |
Process to chiral beta-amino acid derivatives
|
WO2004087053A2
(en)
*
|
2003-03-25 |
2004-10-14 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2004087650A2
(en)
*
|
2003-03-27 |
2004-10-14 |
Merck & Co. Inc. |
Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
|
EP1620091B1
(de)
|
2003-05-05 |
2010-03-31 |
Probiodrug AG |
Glutaminylcyclase-hemmer
|
GB0310593D0
(en)
*
|
2003-05-08 |
2003-06-11 |
Leuven K U Res & Dev |
Peptidic prodrugs
|
CA2524531A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Merck And Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
WO2004110436A1
(en)
*
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
EP1635832A2
(de)
*
|
2003-06-06 |
2006-03-22 |
Merck & Co., Inc. |
Kombinationstherapie zur behandlung von diabetes
|
WO2004112701A2
(en)
*
|
2003-06-17 |
2004-12-29 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JO2625B1
(en)
*
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
KR20060056944A
(ko)
|
2003-07-14 |
2006-05-25 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
|
EP2085406A1
(de)
*
|
2003-07-25 |
2009-08-05 |
ConjuChem Biotechnologies Inc. |
Langanhaltende Insulinderivate und Verfahren dafür
|
EP1651623B1
(de)
*
|
2003-07-31 |
2008-12-17 |
Merck & Co., Inc. |
Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1506967B1
(de)
*
|
2003-08-13 |
2007-11-21 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl Peptidase Inhibitoren.
|
US20060287528A1
(en)
*
|
2003-09-02 |
2006-12-21 |
Wenslow Robert M |
Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
|
EP1697342A2
(de)
*
|
2003-09-08 |
2006-09-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitoren
|
JP2007505121A
(ja)
*
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
CN1902177A
(zh)
|
2003-09-22 |
2007-01-24 |
万有制药株式会社 |
新哌啶衍生物
|
EP1667524A4
(de)
*
|
2003-09-23 |
2009-01-14 |
Merck & Co Inc |
Neue kristalline form eines phosphorsäuresalzes eines hemmstoffs der dipeptidylpeptidase iv
|
WO2005042003A1
(en)
*
|
2003-10-24 |
2005-05-12 |
Merck & Co., Inc. |
Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
|
WO2005049027A2
(en)
|
2003-11-03 |
2005-06-02 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
US7238683B2
(en)
*
|
2003-11-04 |
2007-07-03 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
NZ547752A
(en)
*
|
2003-11-12 |
2009-12-24 |
Phenomix Corp |
Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
|
AU2004290897B2
(en)
|
2003-11-17 |
2009-02-26 |
Novartis Ag |
Use of dipeptidyl peptidase IV inhibitors
|
US20080227786A1
(en)
*
|
2004-01-16 |
2008-09-18 |
Ferlita Russell R |
Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
|
BRPI0507007A
(pt)
|
2004-01-20 |
2007-06-05 |
Novartis Ag |
formulação e processo de compressão direta
|
EP1712547B1
(de)
*
|
2004-02-05 |
2011-12-14 |
Kyorin Pharmaceutical Co., Ltd. |
Bicycloesterderivat
|
KR101099206B1
(ko)
|
2004-02-05 |
2011-12-27 |
프로비오드룩 아게 |
신규한 글루타미닐 시클라제 저해제
|
CN1922139B
(zh)
*
|
2004-02-18 |
2010-12-29 |
杏林制药株式会社 |
双环酰胺衍生物
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CA2557275C
(en)
*
|
2004-02-27 |
2012-06-05 |
Kyorin Pharmaceutical Co., Ltd. |
Bicyclo derivative
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005095381A1
(en)
|
2004-03-15 |
2005-10-13 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US20080255216A1
(en)
|
2004-03-29 |
2008-10-16 |
Aster Susan D |
Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
TW200602293A
(en)
|
2004-04-05 |
2006-01-16 |
Merck & Co Inc |
Process for the preparation of enantiomerically enriched beta amino acid derivatives
|
WO2005108382A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Merck & Co., Inc. |
1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
AU2005247895A1
(en)
*
|
2004-05-18 |
2005-12-08 |
Merck & Co., Inc. |
Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
EP1753730A1
(de)
*
|
2004-06-04 |
2007-02-21 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidasehemmer
|
US7482336B2
(en)
*
|
2004-06-21 |
2009-01-27 |
Merck & Co., Inc. |
Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7842707B2
(en)
*
|
2004-07-23 |
2010-11-30 |
Nuada, Llc |
Peptidase inhibitors
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
EP1797034B1
(de)
|
2004-08-06 |
2010-06-30 |
Merck Sharp & Dohme Corp. |
Sulfonylverbindungen als hemmer von 11-beta-hydroxysteroiddehydrogenase-1
|
EP1784188B1
(de)
*
|
2004-08-23 |
2010-07-14 |
Merck Sharp & Dohme Corp. |
Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
|
US20070259927A1
(en)
*
|
2004-08-26 |
2007-11-08 |
Takeda Pharmaceutical Company Limited |
Remedy for Diabetes
|
AR050615A1
(es)
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
WO2006033848A1
(en)
*
|
2004-09-15 |
2006-03-30 |
Merck & Co., Inc. |
Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
CN101031300A
(zh)
|
2004-10-01 |
2007-09-05 |
默克公司 |
用于治疗或预防糖尿病的作为二肽基肽酶-ⅳ抑制剂的氨基哌啶化合物
|
BRPI0516340A
(pt)
*
|
2004-10-12 |
2008-09-16 |
Glenmark Pharmaceuticals Sa |
composto, composição farmacêutica, método para tratar uma condição que é regulada ou normalizada via inibição de dpp-iv, método para tratar um distúrbio metabólico, método para tratar diabete tipo ii, método para diminuir glicose no sangue, método para tratamento e profilaxia de uma doença, método para tratar toleráncia não prejudicada a glicose insulino-resistente, método para a manufatura de uma composição farmacêutica e processo para a preparação de compostos
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
IN2014CN03629A
(de)
|
2004-11-17 |
2015-09-04 |
Neuralstem Inc |
|
EP2805953B1
(de)
|
2004-12-21 |
2016-03-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-Peptidase-Hemmer
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
JP5091106B2
(ja)
*
|
2005-03-08 |
2012-12-05 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病の治療のためのロフルミラスト
|
TWI357902B
(en)
*
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
US20090306037A1
(en)
*
|
2005-05-02 |
2009-12-10 |
Merck & Co., Inc. |
Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CN101500573A
(zh)
*
|
2005-05-25 |
2009-08-05 |
默克公司 |
用于糖尿病治疗或者预防的作为二肽基肽酶-ⅳ抑制剂的氨基环己烷
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
JP4915833B2
(ja)
*
|
2005-07-01 |
2012-04-11 |
雪印メグミルク株式会社 |
ジペプチジルペプチダーゼiv阻害剤
|
EP1912946B1
(de)
*
|
2005-07-20 |
2009-05-27 |
Eli Lilly And Company |
Pyridinderivate als dipeptedyl-peptidase-hemmer
|
US8076514B2
(en)
|
2005-07-20 |
2011-12-13 |
Eli Lilly And Company |
Phenyl compounds and their use in the treatment of Type II diabetes
|
EP1910317B1
(de)
*
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino-verbundene verbindungen
|
EP1909776A2
(de)
*
|
2005-07-25 |
2008-04-16 |
Merck & Co., Inc. |
Dodecylsulfatsalz eines dipeptidyl-peptidase-iv-hemmers
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
JPWO2007018248A1
(ja)
|
2005-08-10 |
2009-02-19 |
萬有製薬株式会社 |
ピリドン化合物
|
DE602006017712D1
(de)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
Phenylpyridonderivat
|
TW200800213A
(en)
|
2005-09-02 |
2008-01-01 |
Abbott Lab |
Novel imidazo based heterocycles
|
US20090264426A1
(en)
|
2005-09-07 |
2009-10-22 |
Shunji Sakuraba |
Bicyclic aromatic substituted pyridone derivative
|
EP1942898B2
(de)
*
|
2005-09-14 |
2014-05-14 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
|
MY159522A
(en)
*
|
2005-09-14 |
2017-01-13 |
Takeda Pharmaceuticals Co |
Administration of dipeptidyl peptidase inhibitors
|
EP1924567B1
(de)
|
2005-09-16 |
2012-08-22 |
Takeda Pharmaceutical Company Limited |
Verfahren zur herstellung von pyrimidindionderivaten
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
CA2625646A1
(en)
*
|
2005-10-25 |
2007-05-03 |
Merck & Co., Inc. |
Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
|
US8163770B2
(en)
|
2005-10-27 |
2012-04-24 |
Msd. K. K. |
Benzoxathiin derivative
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
EP1962827A4
(de)
|
2005-12-16 |
2011-02-16 |
Merck Sharp & Dohme |
Pharmazeutische zusammensetzungen von kombinationen von dipeptidyl-peptidase-4-hemmern mit metformin
|
EP1801098A1
(de)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
JP5094416B2
(ja)
*
|
2005-12-28 |
2012-12-12 |
武田薬品工業株式会社 |
糖尿病治療剤
|
BRPI0620844A2
(pt)
*
|
2005-12-30 |
2011-11-29 |
Ranbaxy Lab Ltd |
compostos antagonistas dos receptores muscarìnicos, seus métodos de preparação, composições farmacêuticas compreendendo os mesmos, usos dos referidos compostos na preparação de medicamentos
|
US20090156465A1
(en)
|
2005-12-30 |
2009-06-18 |
Sattigeri Jitendra A |
Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
|
WO2007087231A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Merck & Co., Inc. |
Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US7915427B2
(en)
*
|
2006-03-08 |
2011-03-29 |
Kyorin Pharmaceuticals Co., Ltd. |
Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2007112368A1
(en)
*
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
EP2402750A1
(de)
*
|
2006-04-11 |
2012-01-04 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung des GPR119-Rezeptors zur Identifizierung von Verbindungen zur Erhöhung der Knochenmasse bei einer Person
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
CA2643659A1
(en)
|
2006-04-11 |
2007-10-18 |
Novartis Ag |
Organic compounds
|
PE20080251A1
(es)
*
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
CN103951667A
(zh)
|
2006-05-04 |
2014-07-30 |
勃林格殷格翰国际有限公司 |
多晶型
|
JP2010502670A
(ja)
|
2006-09-07 |
2010-01-28 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病のための組合せ治療
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
DK2073810T3
(da)
*
|
2006-09-13 |
2011-10-31 |
Takeda Pharmaceutical |
Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
JPWO2008038692A1
(ja)
|
2006-09-28 |
2010-01-28 |
萬有製薬株式会社 |
ジアリールケチミン誘導体
|
US8278345B2
(en)
|
2006-11-09 |
2012-10-02 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
SI2091948T1
(sl)
|
2006-11-30 |
2012-07-31 |
Probiodrug Ag |
Novi inhibitorji glutaminil ciklaze
|
EP1935420A1
(de)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
|
KR20080071476A
(ko)
*
|
2007-01-30 |
2008-08-04 |
주식회사 엘지생명과학 |
신규한 디펩티딜 펩티데이즈 iv(dpp-iv) 저해제
|
DK2107905T3
(da)
*
|
2007-02-01 |
2011-01-31 |
Takeda Pharmaceutical |
Fast sammensætning omfattende alogliptin og pioglitazon
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
WO2008114857A1
(ja)
*
|
2007-03-22 |
2008-09-25 |
Kyorin Pharmaceutical Co., Ltd. |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
EP2145884B1
(de)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledionderivat
|
WO2008120813A1
(ja)
|
2007-04-03 |
2008-10-09 |
Mitsubishi Tanabe Pharma Corporation |
ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用
|
EP2865670B1
(de)
|
2007-04-18 |
2017-01-11 |
Probiodrug AG |
Thioharnstoffderivative als Glutaminylcyclaseinhibitoren
|
AU2008248186B2
(en)
|
2007-05-07 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
WO2008141021A1
(en)
*
|
2007-05-08 |
2008-11-20 |
Concert Pharmaceuticals, Inc. |
Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
|
EA021544B1
(ru)
|
2007-06-04 |
2015-07-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Триарильные соединения и фармацевтические композиции, их содержащие
|
CN103601792B
(zh)
|
2007-06-04 |
2016-06-29 |
协同医药品公司 |
有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CN101318922B
(zh)
*
|
2007-06-08 |
2010-11-10 |
上海阳帆医药科技有限公司 |
一类二肽基肽酶抑制剂、合成方法和用途
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
NZ600126A
(en)
*
|
2007-08-17 |
2013-12-20 |
Boehringer Ingelheim Int |
Purine derivatives for use in the treatment of fap-related diseases
|
CN101397300B
(zh)
*
|
2007-09-04 |
2011-04-27 |
山东轩竹医药科技有限公司 |
二肽酶-ⅳ抑制剂衍生物
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
CN101417999A
(zh)
*
|
2007-10-25 |
2009-04-29 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
US8334385B2
(en)
*
|
2007-11-02 |
2012-12-18 |
Glenmark Generics Limited |
Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
|
US20090192326A1
(en)
*
|
2007-11-13 |
2009-07-30 |
Nurit Perlman |
Preparation of sitagliptin intermediate
|
WO2009085990A2
(en)
*
|
2007-12-20 |
2009-07-09 |
Dr. Reddy's Laboratories Limited |
Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
|
US8470836B2
(en)
*
|
2007-12-21 |
2013-06-25 |
Lg Life Sciences, Ltd. |
Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
|
CN101468988A
(zh)
*
|
2007-12-26 |
2009-07-01 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
WO2009093269A1
(en)
*
|
2008-01-24 |
2009-07-30 |
Panacea Biotec Limited |
Novel heterocyclic compounds
|
JP2011510986A
(ja)
*
|
2008-02-05 |
2011-04-07 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メトホルミン及びジペプチジルペプチダーゼ−iv阻害剤の併用医薬組成物
|
WO2009111200A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Merck & Co., Inc. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
EP2264026A4
(de)
|
2008-03-06 |
2012-03-28 |
Msd Kk |
Alkylaminopyridinderivate
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
EP2272841A1
(de)
|
2008-03-28 |
2011-01-12 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamidderivat mit antagonistischer wirkung auf rezeptor des melaninkonzentrierenden hormons
|
US20090247532A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Mae De Ltd. |
Crystalline polymorph of sitagliptin phosphate and its preparation
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(de)
*
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
|
EP2110374A1
(de)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
|
US20090264476A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Mckelvey Craig |
CB-1 receptor modulator formulations
|
US8003672B2
(en)
*
|
2008-04-21 |
2011-08-23 |
Merck Sharp & Dohme Corp. |
CB-1 receptor modulator formulations
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
AU2009261248A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
EP2650297A1
(de)
|
2008-07-03 |
2013-10-16 |
Ratiopharm GmbH |
Kristalline Salze von Sitagliptin
|
EP3241839B1
(de)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
WO2010012781A2
(en)
*
|
2008-07-29 |
2010-02-04 |
Medichem, S.A. |
New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
|
JPWO2010013595A1
(ja)
|
2008-07-30 |
2012-01-12 |
Msd株式会社 |
5員−5員又は5員−6員縮環シクロアルキルアミン誘導体
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
WO2010016584A1
(ja)
*
|
2008-08-07 |
2010-02-11 |
杏林製薬株式会社 |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
CN102186474A
(zh)
*
|
2008-08-14 |
2011-09-14 |
杏林制药株式会社 |
稳定的医药组合物
|
MX2011001525A
(es)
|
2008-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
US8476437B2
(en)
*
|
2008-08-27 |
2013-07-02 |
Cadila Healthcare Limited |
Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof
|
BRPI0919288A2
(pt)
|
2008-09-10 |
2015-12-15 |
Boehring Ingelheim Internat Gmbh |
teriapia de combinação para tratamento de diabetes e condições relacionadas.
|
AU2009298617A1
(en)
|
2008-10-03 |
2010-04-08 |
Schering Corporation |
Spiro-imidazolone derivatives as glucagon receptor antagonists
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
KR101054911B1
(ko)
*
|
2008-10-17 |
2011-08-05 |
동아제약주식회사 |
디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
|
MX2011004258A
(es)
|
2008-10-22 |
2011-06-01 |
Merck Sharp & Dohme |
Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
|
CA2741644C
(en)
|
2008-10-30 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
US8759539B2
(en)
|
2008-11-17 |
2014-06-24 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
MX2011006713A
(es)
|
2008-12-23 |
2011-07-13 |
Boehringer Ingelheim Int |
Formas salinas de compuesto organico.
|
CN102271504B
(zh)
*
|
2008-12-31 |
2014-08-20 |
凯瑞斯德股份有限公司 |
用于制备N-酰化-4-芳基β-氨基酸衍生物的方法和中间体
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
US8404727B2
(en)
*
|
2009-01-07 |
2013-03-26 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
|
WO2010079413A2
(en)
|
2009-01-09 |
2010-07-15 |
Orchid Research Laboratories Ltd. |
Dipeptidyl peptidase iv inhibitors
|
AR075204A1
(es)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
|
EP2218721A1
(de)
|
2009-02-11 |
2010-08-18 |
LEK Pharmaceuticals d.d. |
Neuartige Salze von Sitagliptin
|
MX339194B
(es)
|
2009-02-13 |
2016-05-16 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
|
CN102387795A
(zh)
|
2009-02-13 |
2012-03-21 |
贝林格尔.英格海姆国际有限公司 |
包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
|
EP2223923A1
(de)
|
2009-02-25 |
2010-09-01 |
Esteve Química, S.A. |
Verfahren zur Herstellung eines chiralen Beta-Aminosäurederivats und Zwischenprodukte davon
|
CN101824036A
(zh)
*
|
2009-03-05 |
2010-09-08 |
上海恒瑞医药有限公司 |
四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
|
ES2571443T3
(es)
*
|
2009-03-30 |
2016-05-25 |
Dong A St Co Ltd |
Método mejorado para la fabricación de un inhibidor de la dipeptidil peptidasa-IV y de un intermedio
|
NZ608028A
(en)
|
2009-03-30 |
2014-09-26 |
Dong A Pharm Co Ltd |
Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate
|
CN101849944A
(zh)
*
|
2009-03-31 |
2010-10-06 |
江苏恒瑞医药股份有限公司 |
治疗2型糖尿病的药物组合物
|
WO2010122578A2
(en)
*
|
2009-04-20 |
2010-10-28 |
Msn Laboratories Limited |
Process for the preparation of sitagliptin and its intermediates
|
CN102574856B
(zh)
*
|
2009-05-11 |
2016-09-21 |
基因里克斯(英国)有限公司 |
西他列汀的合成
|
CN101899047B
(zh)
*
|
2009-05-26 |
2016-01-20 |
盛世泰科生物医药技术(苏州)有限公司 |
作为二肽基肽酶抑制剂用于治疗或预防糖尿病的β-氨基四氢吡嗪、四氢嘧啶和四氢吡啶
|
CN101899048B
(zh)
*
|
2009-05-27 |
2013-04-17 |
上海恒瑞医药有限公司 |
(R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
|
EP2440553B1
(de)
|
2009-06-12 |
2017-08-23 |
Merck Sharp & Dohme Corp. |
Thiophene als glucagonrezeptorantagonisten, zusammensetzungen und verfahren zu ihrer verwendung
|
IT1395596B1
(it)
|
2009-06-30 |
2012-10-16 |
Dipharma Francis Srl |
Procedimento per la preparazione di sitagliptin
|
TWI421252B
(zh)
|
2009-07-09 |
2014-01-01 |
Irm Llc |
用於治療寄生蟲疾病之化合物及組合物
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
CN102470166B
(zh)
|
2009-08-03 |
2014-04-09 |
株式会社钟化 |
二肽基肽酶-4抑制剂
|
MX2012001842A
(es)
*
|
2009-08-13 |
2012-03-07 |
Sandoz Ag |
Compuesto cristalino de 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorofe nil))butil]-5,6,7,8-tetrahidro-3-(trifluorometil)-1,2,4-triazolo[ 4,3-a]pirazina.
|
EP2464228B1
(de)
|
2009-08-13 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit
|
IN2012DN00721A
(de)
|
2009-09-02 |
2015-06-19 |
Merck Sharp & Dohme |
|
PL2475428T3
(pl)
|
2009-09-11 |
2015-12-31 |
Probiodrug Ag |
Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
|
EP2295083A1
(de)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
|
CN102030683B
(zh)
*
|
2009-09-27 |
2013-07-31 |
浙江九洲药业股份有限公司 |
西他列汀中间体及其制备方法和用途
|
EP2308847B1
(de)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituierte Pyridine als Inhibitoren der Dipeptidyl Peptidase IV und ihre Anwendung für die Behandlung von Diabetes und verwandten Krankheiten
|
WO2011058193A1
(en)
|
2009-11-16 |
2011-05-19 |
Mellitech |
[1,5]-diazocin derivatives
|
KR20230021159A
(ko)
|
2009-11-27 |
2023-02-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
CN103664873B
(zh)
|
2009-12-30 |
2016-06-15 |
深圳信立泰药业股份有限公司 |
作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
|
KR101156587B1
(ko)
|
2010-02-19 |
2012-06-20 |
한미사이언스 주식회사 |
시타글립틴의 제조방법 및 이에 사용되는 아민염 중간체
|
EP2538783B1
(de)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituierte aminotetrahydrothiopyrane als dipeptidylpeptidase-iv-hemmer zur behandlung von diabetes
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EP2542549B1
(de)
|
2010-03-03 |
2016-05-11 |
Probiodrug AG |
Glutaminylcyclase-hemmer
|
CA2789440C
(en)
|
2010-03-10 |
2020-03-24 |
Probiodrug Ag |
Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
|
CZ303113B6
(cs)
|
2010-03-16 |
2012-04-11 |
Zentiva, K.S. |
Zpusob prípravy sitagliptinu
|
JP2013522279A
(ja)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
|
US8183373B2
(en)
|
2010-03-31 |
2012-05-22 |
Teva Pharmaceutical Industries Ltd. |
Solid state forms of sitagliptin salts
|
CN102946726B
(zh)
*
|
2010-04-05 |
2015-08-19 |
卡帝拉药物有限公司 |
新型降血糖化合物
|
MX2012011631A
(es)
|
2010-04-06 |
2013-01-18 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
EP2566843B1
(de)
*
|
2010-04-28 |
2017-03-29 |
Sun Pharmaceutical Industries Limited |
Verfahren zur herstellung chiraler beta-aminocarboxamid-derivate
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
EP2392575A1
(de)
|
2010-06-04 |
2011-12-07 |
LEK Pharmaceuticals d.d. |
Neuartiger synthetischer Ansatz für ß-Aminobutyryl-substituierte Verbindungen
|
WO2011151443A1
(en)
|
2010-06-04 |
2011-12-08 |
Lek Pharmaceuticals D.D. |
A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS
|
EP2397141A1
(de)
|
2010-06-16 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
Verfahren zur Synthese von Beta-Aminosäuren und Derivaten daraus
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
EP2407469A1
(de)
|
2010-07-13 |
2012-01-18 |
Chemo Ibérica, S.A. |
Sitagliptinsalz
|
EP2423178A1
(de)
|
2010-07-28 |
2012-02-29 |
Chemo Ibérica, S.A. |
Verfahren zur Herstellung von Sitagliptin
|
ES2571991T3
(es)
|
2010-07-28 |
2016-05-27 |
Neuralstem Inc |
Procedimientos para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos
|
EP2418196A1
(de)
*
|
2010-07-29 |
2012-02-15 |
IMTM GmbH |
Duale Alanyl-Aminopeptidase and Dipeptidyl-peptidase IV Inhibitoren
|
WO2012024183A1
(en)
|
2010-08-18 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
EP2609099A2
(de)
|
2010-08-27 |
2013-07-03 |
USV Limited |
Sitagliptin, salze und polymorphe davon
|
WO2012035549A2
(en)
|
2010-09-13 |
2012-03-22 |
Panacea Biotec Ltd |
An improved process for the synthesis of beta amino acid derivatives
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EA201390421A1
(ru)
|
2010-09-22 |
2013-09-30 |
Арена Фармасьютикалз, Инк. |
Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
|
EP2625179A2
(de)
|
2010-10-08 |
2013-08-14 |
Cadila Healthcare Limited |
Verfahren zur herstellung eines sitagliptin-zwischenprodukts durch enzymatische umwandlung
|
WO2012049566A1
(en)
|
2010-10-14 |
2012-04-19 |
Japan Tobacco Inc. |
Combination therapy for use in treating diabetes
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102485718B
(zh)
|
2010-12-03 |
2014-03-26 |
浙江海翔药业股份有限公司 |
西他列汀的中间体及其制备方法
|
US8691832B2
(en)
|
2010-12-06 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
|
WO2012076973A2
(en)
|
2010-12-09 |
2012-06-14 |
Aurobindo Pharma Limited |
Novel salts of dipeptidyl peptidase iv inhibitor
|
TWI494313B
(zh)
*
|
2010-12-29 |
2015-08-01 |
Jiangsu Hengrui Medicine Co |
治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物
|
ES2834986T3
(es)
|
2011-01-07 |
2021-06-21 |
Anji Pharma Us Llc |
Terapias basadas en ligandos de receptores quimiosensoriales
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
KR101290029B1
(ko)
*
|
2011-01-20 |
2013-07-30 |
에스티팜 주식회사 |
시타글립틴의 중간체 제조방법
|
KR101733414B1
(ko)
|
2011-01-31 |
2017-05-10 |
카딜라 핼쓰캐어 리미티드 |
지방이상증의 치료
|
KR20150075120A
(ko)
|
2011-02-25 |
2015-07-02 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
|
CN107090016A
(zh)
|
2011-03-01 |
2017-08-25 |
辛纳吉制药公司 |
制备鸟苷酸环化酶c激动剂的方法
|
DK2681220T3
(en)
|
2011-03-03 |
2015-11-30 |
Cadila Healthcare Ltd |
PRESENT UNKNOWN SALTS OF DPP-IV INHIBITOR
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
WO2012131005A1
(en)
|
2011-03-29 |
2012-10-04 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Pharmaceutical composition of sitagliptin
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
EP2508506A1
(de)
|
2011-04-08 |
2012-10-10 |
LEK Pharmaceuticals d.d. |
Herstellung von Sitagliptin-Zwischenprodukten
|
EP2693882B1
(de)
|
2011-04-08 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit
|
KR101369584B1
(ko)
|
2011-04-19 |
2014-03-06 |
일양약품주식회사 |
페닐-이속사졸 유도체 및 그의 제조방법
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
CN102757431B
(zh)
*
|
2011-04-24 |
2016-03-30 |
浙江华海药业股份有限公司 |
一种合成西他列汀的新方法
|
ITMI20110765A1
(it)
|
2011-05-05 |
2012-11-06 |
Chemo Iberica Sa |
Processo per la produzione di sitagliptina
|
US8524936B2
(en)
|
2011-05-18 |
2013-09-03 |
Milan Soukup |
Manufacturing process for sitagliptin from L-aspartic acid
|
EP2527320A1
(de)
|
2011-05-27 |
2012-11-28 |
LEK Pharmaceuticals d.d. |
Herstellung von Sitagliptin-Zwischenprodukten
|
US9359385B2
(en)
*
|
2011-05-27 |
2016-06-07 |
Lek Pharmaceuticals D.D. |
Preparation of sitagliptin intermediates
|
CA2837517A1
(en)
|
2011-06-02 |
2012-12-06 |
Intervet International B.V. |
Imidazole derivatives
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
AR086675A1
(es)
*
|
2011-06-14 |
2014-01-15 |
Merck Sharp & Dohme |
Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
|
AU2012271009A1
(en)
|
2011-06-16 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
EP2725905A4
(de)
|
2011-06-29 |
2014-11-26 |
Merck Sharp & Dohme |
Verfahren zur herstellung von chiralen dipeptidylpeptidase-iv-hemmern
|
US20150025080A1
(en)
|
2011-06-29 |
2015-01-22 |
Ranbaxy Laboratories Limited |
Solid dispersions of sitagliptin and processes for their preparation
|
AU2012277403A1
(en)
|
2011-06-30 |
2014-01-30 |
Ranbaxy Laboratories Limited |
Novel salts of sitagliptin
|
US9051329B2
(en)
|
2011-07-05 |
2015-06-09 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
|
HUE043540T2
(hu)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
|
EA024688B1
(ru)
*
|
2011-07-27 |
2016-10-31 |
ФАРМА ДжРС, Д.О.О. |
Способ получения ситаглиптина и его фармацевтически приемлемых солей
|
WO2013036213A1
(en)
|
2011-09-07 |
2013-03-14 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dpp-iv inhibitor formulations
|
US9422266B2
(en)
|
2011-09-30 |
2016-08-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2578208B1
(de)
|
2011-10-06 |
2014-05-21 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Feste Dosierformulierungen von DPP-IV Inhibitoren
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CN106905321A
(zh)
|
2011-10-14 |
2017-06-30 |
劳乐斯实验室私营有限公司 |
新的西他列汀盐、其制备方法及其药物组合物
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
US9018200B2
(en)
|
2011-10-24 |
2015-04-28 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as GPR119 agonists
|
CN102603749B
(zh)
*
|
2011-10-27 |
2017-02-08 |
浙江华海药业股份有限公司 |
一种西他列汀中间体的合成方法
|
WO2013065066A1
(en)
|
2011-11-02 |
2013-05-10 |
Cadila Healthcare Limited |
Processes for preparing 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,41-triazolo[43-a]pyrazin-7(8h)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
CA2855009C
(en)
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
WO2013084210A1
(en)
|
2011-12-08 |
2013-06-13 |
Ranbaxy Laboratories Limited |
Amorphous form of sitagliptin salts
|
KR20200137035A
(ko)
|
2012-01-06 |
2020-12-08 |
앤지 파마 유에스 엘엘씨 |
바이구아나이드 조성물 및 대사 장애를 치료하는 방법
|
NZ626578A
(en)
|
2012-01-06 |
2016-11-25 |
Elcelyx Therapeutics Inc |
Compositions and methods for treating metabolic disorders
|
EP2615080A1
(de)
|
2012-01-12 |
2013-07-17 |
LEK Pharmaceuticals d.d. |
Herstellung von optisch reinen aktiven pharmazeutischen Bestandteilen des ß-Aminosäuretyps und Zwischenverbindungen davon
|
EP2814485A4
(de)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
Dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
|
ES2421956B1
(es)
|
2012-03-02 |
2014-09-29 |
Moehs Ibérica S.L. |
Nueva forma cristalina de sulfato de sitagliptina
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
CN104411710A
(zh)
|
2012-04-16 |
2015-03-11 |
卡内克制药公司 |
作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
|
TWI469785B
(zh)
|
2012-04-25 |
2015-01-21 |
Inovobiologic Inc |
用於治療代謝性疾病之膳食纖維組成物
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2674432A1
(de)
|
2012-06-14 |
2013-12-18 |
LEK Pharmaceuticals d.d. |
Neuer synthetischer Weg zur Herstellung von ß-Aminobutyryl-substituierten 5,6,7,8-Tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-YL-Verbindungen
|
EP2874626A4
(de)
|
2012-07-23 |
2016-03-23 |
Merck Sharp & Dohme |
Behandlung von diabetes mit dipeptidylpeptidase-iv-hemmern
|
WO2014018350A1
(en)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-iv inhibitors
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
KR20150056541A
(ko)
|
2012-08-08 |
2015-05-26 |
시플라 리미티드 |
시타글립틴 및 중간체 화합물의 제조 방법
|
CN102898387B
(zh)
*
|
2012-09-26 |
2015-01-07 |
浙江工业大学 |
管道化连续生产n-[(2z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼的方法
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
CN103788070B
(zh)
*
|
2012-10-26 |
2017-10-20 |
南京华威医药科技开发有限公司 |
Dpp‑4抑制剂类多聚物
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
CZ306115B6
(cs)
|
2012-12-04 |
2016-08-10 |
Zentiva, K.S. |
Způsob přípravy derivátů kyseliny 3-amino-4-(2,4,5-trifluorfenyl)-butanové
|
CN103319487B
(zh)
*
|
2013-01-10 |
2015-04-01 |
药源药物化学(上海)有限公司 |
西格列汀的制备方法及其中间体
|
EP2769712A1
(de)
|
2013-02-21 |
2014-08-27 |
Siegfried International AG |
Pharmazeutische Formulierung mit DPP-IV-Agglomeraten und DPP-IV-Hemmerpartikeln
|
MX2015010935A
(es)
|
2013-02-22 |
2015-10-29 |
Merck Sharp & Dohme |
Compuestos biciclicos antidiabeticos.
|
CN105669682B
(zh)
*
|
2013-02-22 |
2019-08-30 |
成都先导药物开发股份有限公司 |
一种dpp-iv抑制剂的中间体
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
IN2013MU00916A
(de)
|
2013-03-20 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2014174524A1
(en)
|
2013-04-22 |
2014-10-30 |
Cadila Healthcare Limited |
A novel composition for nonalcoholic fatty liver disease (nafld)
|
EP3004053B1
(de)
|
2013-05-30 |
2021-03-24 |
Cadila Healthcare Limited |
Verfahren zur herstellung von pyrrolen mit hypolipidämischer hypocholesterämischer aktivität
|
CN105764916B
(zh)
|
2013-06-05 |
2021-05-18 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
WO2015001568A2
(en)
*
|
2013-07-01 |
2015-01-08 |
Laurus Labs Private Limited |
Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
IN2013MU02470A
(de)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
IN2013MU02905A
(de)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CZ2013842A3
(cs)
|
2013-11-01 |
2015-05-13 |
Zentiva, K.S. |
Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
CN103626775B
(zh)
*
|
2013-12-02 |
2015-05-20 |
南京华威医药科技开发有限公司 |
具有二嗪结构的dpp-4抑制剂
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
WO2015114657A2
(en)
|
2014-01-21 |
2015-08-06 |
Cadila Healthcare Limited |
Amorphous form of sitagliptin free base
|
WO2015112465A1
(en)
|
2014-01-24 |
2015-07-30 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as mgat2 inhibitors
|
IN2014MU00651A
(de)
|
2014-02-25 |
2015-10-23 |
Cadila Healthcare Ltd |
|
EP3110449B1
(de)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medizinische verwendung eines dpp-4-inhibitors
|
WO2015145333A1
(en)
|
2014-03-26 |
2015-10-01 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of sitagliptin and its intermediate
|
CN106456998B
(zh)
|
2014-04-17 |
2020-07-28 |
默沙东公司 |
西格列汀丹宁酸盐复合物
|
WO2015162506A1
(en)
|
2014-04-21 |
2015-10-29 |
Suven Life Sciences Limited |
Process for the preparation of sitagliptin and novel intermediates
|
WO2015170340A2
(en)
*
|
2014-05-06 |
2015-11-12 |
Laurus Labs Private Limited |
Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
|
JP6574474B2
(ja)
|
2014-07-21 |
2019-09-11 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
キラルジペプチジルペプチダーゼ−iv阻害剤の製造方法
|
EP3177282B1
(de)
|
2014-08-08 |
2021-10-06 |
Merck Sharp & Dohme Corp. |
Antidiabetische bicyclische verbindungen
|
CN104140430B
(zh)
*
|
2014-08-08 |
2016-07-13 |
广东东阳光药业有限公司 |
一种异构体的消旋方法
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
EP3177287B1
(de)
|
2014-08-08 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
Antidiabetische bicyclische verbindungen
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
WO2016046679A1
(en)
*
|
2014-09-28 |
2016-03-31 |
Mohan M Alapati |
Compositions and methods for the treatment of diabetes and pre-diabetes
|
CN107148275A
(zh)
|
2014-10-20 |
2017-09-08 |
神经干细胞公司 |
包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
EP3242879B1
(de)
|
2015-01-08 |
2019-12-11 |
Lee Pharma Ltd. |
Neuartiges verfahren zur herstellung von dipeptidyl-peptidase-4 (dpp-4)-enzymhemmer
|
CZ27898U1
(cs)
|
2015-01-13 |
2015-03-02 |
Zentiva, K.S. |
Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
|
CZ27930U1
(cs)
|
2015-01-13 |
2015-03-10 |
Zentiva, K.S. |
Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
|
MX2017011586A
(es)
|
2015-03-09 |
2017-10-26 |
Intekrin Therapeutics Inc |
Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
|
BR112017021824A2
(pt)
*
|
2015-04-15 |
2018-07-10 |
Valent Biosciences Llc |
composto enantiomericamente puro, processo de fabricação dos compostos, e, método para regular o crescimento de plantas
|
KR101772898B1
(ko)
|
2015-06-11 |
2017-08-31 |
동방에프티엘(주) |
시타글립틴의 개선된 제조방법
|
KR101709127B1
(ko)
|
2015-06-16 |
2017-02-22 |
경동제약 주식회사 |
Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
|
ES2929526T3
(es)
|
2015-06-22 |
2022-11-29 |
Arena Pharm Inc |
Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
|
CN105017260B
(zh)
*
|
2015-07-30 |
2017-04-19 |
新发药业有限公司 |
一种西他列汀中间体三唑并吡嗪衍生物的制备方法
|
US11000521B2
(en)
|
2015-08-03 |
2021-05-11 |
Institut Pasteur |
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
|
KR20170036288A
(ko)
|
2015-09-24 |
2017-04-03 |
주식회사 종근당 |
시타글립틴의 신규염 및 이의 제조방법
|
WO2017064635A2
(en)
|
2015-10-14 |
2017-04-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
ES2638266T3
(es)
*
|
2015-10-22 |
2017-10-19 |
F.I.S.- Fabbrica Italiana Sintetici S.P.A. |
Procedimiento mejorado para la preparación de triazol y una de sus sales
|
EP3383869B1
(de)
|
2015-11-30 |
2023-06-28 |
Merck Sharp & Dohme LLC |
Arylsulfonamide als blt1-antagonisten
|
WO2017095724A1
(en)
|
2015-11-30 |
2017-06-08 |
Merck Sharp & Dohme Corp. |
Aryl sulfonamides as blt1 antagonists
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
WO2018034918A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
EP3496715B1
(de)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Zur veränderung der konzentrationen von gallensäuren nützliche verbindungen zur behandlung von diabetes und kardiometabolischen erkrankungen
|
CN106124667B
(zh)
*
|
2016-08-29 |
2018-07-31 |
上海应用技术学院 |
一种分离测定西格列汀有关物质的方法
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
MX2016016260A
(es)
|
2016-12-08 |
2018-06-07 |
Alparis Sa De Cv |
Nuevas formas solidas de sitagliptina.
|
ES2894261T3
(es)
|
2016-12-09 |
2022-02-14 |
Cadila Healthcare Ltd |
Tratamiento de la colangitis biliar primaria
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
EP3558298A4
(de)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Antidiabetische spirochromanverbindungen
|
US11197949B2
(en)
*
|
2017-01-19 |
2021-12-14 |
Medtronic Minimed, Inc. |
Medication infusion components and systems
|
US10047094B1
(en)
|
2017-02-10 |
2018-08-14 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Process for the preparation of triazole and salt thereof
|
CA3053418A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
CA3058806A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
Ppar.gamma. agonist for treatment of progressive supranuclear palsy
|
MX2019012758A
(es)
|
2017-04-24 |
2019-12-16 |
Novartis Ag |
Regimen terapeutico de 2-amino-1-(2-(4-fluorofenil)-3-(4-fluorofen ilamino)-8,8-dimetil-5,6-dihidroimidazo [1,2-a]pirazin-7(8h)-il)et anona y combinaciones de la misma.
|
US11096890B2
(en)
|
2017-09-29 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
Chewable dosage forms containing sitagliptin and metformin
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
KR20190060235A
(ko)
|
2017-11-24 |
2019-06-03 |
제일약품주식회사 |
시타글립틴 캄실산염의 제조방법
|
TR201722603A2
(tr)
|
2017-12-28 |
2019-07-22 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
|
CN108586346B
(zh)
|
2018-05-10 |
2019-10-01 |
北京富盛嘉华医药科技有限公司 |
一种生物催化合成西他列汀及其中间体的方法
|
TW202045476A
(zh)
|
2019-02-13 |
2020-12-16 |
美商默沙東藥廠 |
5-烷基吡咯啶食慾素受體促效劑
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
EP4045048A4
(de)
|
2019-10-14 |
2023-05-24 |
Santa Farma Ilaç Sanayi A.S. |
Orale formulierungen mit sitagliptin-hci-monohydrat mit verbesserten pharmazeutischen eigenschaften
|
KR20210057603A
(ko)
|
2019-11-12 |
2021-05-21 |
제이투에이치바이오텍 (주) |
시타글립틴의 제조방법
|
US20230365533A1
(en)
|
2020-08-18 |
2023-11-16 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|
KR102589305B1
(ko)
|
2021-04-22 |
2023-10-16 |
주식회사 메디켐코리아 |
시타글립틴 인산염의 개선된 제조방법
|
CN113979896A
(zh)
*
|
2021-11-18 |
2022-01-28 |
浙江永太手心医药科技有限公司 |
一种西格列汀杂质i及其制备方法
|
WO2023139276A1
(en)
|
2022-01-24 |
2023-07-27 |
Zaklady Farmaceutyczne Polpharma S.A. |
Process for preparing crystalline sitagliptin hydrochloride monohydrate
|